1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on May 18, 2025

Sanofi: Information concerning the total number of voting rights and shares - April 2025
SNY

GlobeNewswire

2 days ago

Sanofi: Information concerning the total number of voting rights and shares - April 2025

French finance minister criticises Sanofi's $20 billion USA investment decision
SNY

Reuters

2 days ago

French finance minister criticises Sanofi's $20 billion USA investment decision

Sanofi commits ‘at least $20bn’ to US manufacturing through 2030
SNY

Pharmaceutical Technology

3 days ago

Sanofi commits ‘at least $20bn’ to US manufacturing through 2030

Sanofi to pour more than $20B into US drug research and manufacturing
SNY

BioPharma Dive

3 days ago

Sanofi to pour more than $20B into US drug research and manufacturing

SNY

MT Newswires

3 days ago

Sanofi to Invest at Least $20 Billion in US Through 2030

France's Sanofi to invest at least $20 billion in US through 2030
SNY

Reuters

3 days ago

France's Sanofi to invest at least $20 billion in US through 2030

Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
SNY

PR Newswire

3 days ago

Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing

Sanofi (SNY): A Bull Case Theory
SNY

Insider Monkey

4 days ago

Sanofi (SNY): A Bull Case Theory

SNY

Morningstar Research

5 days ago

Analyst Report: Sanofi

SNY

MT Newswires

5 days ago

Bristol-Myers Squibb, Sanofi Enter $700 Million Settlement With Hawaii in Plavix Lawsuit

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower
SNY

Bloomberg

6 days ago

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
SNY

Bloomberg

6 days ago

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

SNY

Associated Press Finance

8 days ago

Drug companies to pay Hawaii $700 million to settle Plavix blood thinner lawsuit

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
SNY

Zacks

8 days ago

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
SNY

Benzinga

9 days ago

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

Sanofi exec tells biotechs not to scrimp on clinical trial design
SNY

Clinical Trials Arena

9 days ago

Sanofi exec tells biotechs not to scrimp on clinical trial design

Novavax to Report First-Quarter Earnings: Is a Beat in Store?
SNY

Zacks

13 days ago

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

European Firms Fare Better Than Feared Through Early Trade Pain
SNY

Bloomberg

13 days ago

European Firms Fare Better Than Feared Through Early Trade Pain

Sanofi: Information concerning the total number of voting rights and shares - March 2025
SNY

GlobeNewswire

15 days ago

Sanofi: Information concerning the total number of voting rights and shares - March 2025

Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair
SNY

Simply Wall St.

16 days ago

Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader
SNY

GuruFocus.com

17 days ago

Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader

SNY

MT Newswires

17 days ago

Sanofi Closes Sale of Controlling Stake in Opella to CD&R

Press Release: Annual General Meeting of April 30, 2025
SNY

GlobeNewswire

17 days ago

Press Release: Annual General Meeting of April 30, 2025

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
SNY

GlobeNewswire

18 days ago

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

SNY

GuruFocus.com

18 days ago

Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down
SNY

Zacks

18 days ago

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Regeneron's first-quarter results miss on lower Eylea demand
SNY

Reuters

19 days ago

Regeneron's first-quarter results miss on lower Eylea demand

SNY

Argus Research

19 days ago

Market Digest: SNY, CLS, DPZ, GE, DOC, ROP, SAP, TMO, AGNC

SNY

Argus Research

19 days ago

Analyst Report: Sanofi SA

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
SNY

GlobeNewswire

19 days ago

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Private Equity Firms Target Defense Assets Once Seen as Toxic
SNY

Bloomberg

20 days ago

Private Equity Firms Target Defense Assets Once Seen as Toxic

Halozyme sues Merck; FDA blames cuts for Vanda delay
SNY

BioPharma Dive

23 days ago

Halozyme sues Merck; FDA blames cuts for Vanda delay

Swiss Agree to Tariff Negotiations With Trump Administration
SNY

Bloomberg

23 days ago

Swiss Agree to Tariff Negotiations With Trump Administration

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed
SNY

Investor's Business Daily

23 days ago

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail
SNY

Clinical Trials Arena

23 days ago

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
SNY

Benzinga

23 days ago

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

SNY

MT Newswires

23 days ago

Sector Update: Health Care Stocks Steady Pre-Bell Thursday

Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
SNY

Zacks

24 days ago

Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

Sanofi stays on course amid tariff turmoil
SNY

BioPharma Dive

24 days ago

Sanofi stays on course amid tariff turmoil

SNY

MT Newswires

24 days ago

Sanofi's Q1 Earnings, Revenue Rise; 2025 Guidance Confirmed

SNY

MT Newswires

24 days ago

Innate Pharma, Sanofi Finalize Investment

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
SNY

The Wall Street Journal

24 days ago

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

SNY

GlobeNewswire

24 days ago

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

SNY

MT Newswires

25 days ago

Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement

European pharma companies push for higher drug prices in EU amid U.S. tariff threats
SNY

Reuters

25 days ago

European pharma companies push for higher drug prices in EU amid U.S. tariff threats

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
SNY

Zacks

25 days ago

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria
SNY

Zacks

a month ago

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

SNY

MT Newswires

a month ago

FDA Approves Dupixent for Chronic Hives in Patients Unresponsive to Antihistamines

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
SNY

Pharmaceutical Technology

a month ago

Sanofi and Regeneron’s dupilumab approved by FDA for urticaria

Regeneron, Sanofi announce FDA approval of Dupixent for CSU
SNY

TipRanks

a month ago

Regeneron, Sanofi announce FDA approval of Dupixent for CSU

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
SNY

GlobeNewswire

a month ago

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
SNY

GlobeNewswire

a month ago

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
SNY

BioPharma Dive

a month ago

Sanofi, Regeneron win FDA nod for Dupixent in chronic hives

SNY

MT Newswires

a month ago

Sanofi, Earendil Labs Sign Licensing Deal for Autoimmune, Inflammatory Bowel Disease Treatments

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback
SNY

Zacks

a month ago

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

Sanofi licenses immune disease drugs from startup Earendil
SNY

BioPharma Dive

a month ago

Sanofi licenses immune disease drugs from startup Earendil

Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
SNY

Zacks

a month ago

Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement
SNY

PR Newswire

a month ago

Chrissy Teigen - author, entrepreneur, mom to young son with type 1 diabetes - joins Sanofi's Screen For Type 1 movement

Tariff wars to hit popular US-made drugs in China, regulator data shows
SNY

Reuters

a month ago

Tariff wars to hit popular US-made drugs in China, regulator data shows

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
SNY

GlobeNewswire

a month ago

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Why You Shouldn't Bet Against Sanofi (SNY) Stock
SNY

Zacks

a month ago

Why You Shouldn't Bet Against Sanofi (SNY) Stock

AAN 2025: Sanofi’s tolebrutinib likely to be first BTK inhibitor for the treatment of MS
SNY

Clinical Trials Arena

a month ago

AAN 2025: Sanofi’s tolebrutinib likely to be first BTK inhibitor for the treatment of MS

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
SNY

Bloomberg

a month ago

Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
SNY

GlobeNewswire

a month ago

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis

Tariffs Stoke Fears That Hung Debt Will Return
SNY

Bloomberg

a month ago

Tariffs Stoke Fears That Hung Debt Will Return

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure
SNY

Zacks

a month ago

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
SNY

Pharmaceutical Technology

a month ago

FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions

Sanofi: Information concerning the total number of voting rights and shares - February 2025
SNY

GlobeNewswire

a month ago

Sanofi: Information concerning the total number of voting rights and shares - February 2025

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
SNY

Zacks

a month ago

SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
SNY

Zacks

a month ago

NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
SNY

GlobeNewswire

a month ago

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Leqembi’s EU review drags on; Sanofi gets a new development head
SNY

BioPharma Dive

2 months ago

Leqembi’s EU review drags on; Sanofi gets a new development head

SNY

MT Newswires

2 months ago

Nurix Therapeutics Signs Exclusive Licensing Deal With Sanofi for Autoimmune Disease Program

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?
SNY

Insider Monkey

2 months ago

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
SNY

Zacks

2 months ago

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
SNY

Pharmaceutical Technology

2 months ago

Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients

FDA Approves Sanofi's Hemophilia Drug
SNY

Benzinga

2 months ago

FDA Approves Sanofi's Hemophilia Drug

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
SNY

GlobeNewswire

2 months ago

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

SNY

MT Newswires

2 months ago

Sanofi Hemophilia Treatment Receives FDA Approval

US FDA approves Sanofi's bleeding disorder therapy
SNY

Reuters

2 months ago

US FDA approves Sanofi's bleeding disorder therapy

FDA approves first-of-its-kind RNA drug for hemophilia
SNY

BioPharma Dive

2 months ago

FDA approves first-of-its-kind RNA drug for hemophilia

SNY

MT Newswires

2 months ago

Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...
SNY

GuruFocus.com

2 months ago

Innate Pharma SA (IPHA) (FY 2024) Earnings Call Highlights: Strategic Advances and Financial ...

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
SNY

GlobeNewswire

2 months ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
SNY

GlobeNewswire

2 months ago

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

SNY

Morningstar Research

2 months ago

Analyst Report: Sanofi

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
SNY

Zacks

2 months ago

Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive

U.S. to end funding for child vaccines in developing countries, NY Times reports
SNY

TipRanks

2 months ago

U.S. to end funding for child vaccines in developing countries, NY Times reports

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
SNY

Fortune

2 months ago

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate

SNY

Morningstar Research

2 months ago

Analyst Report: Sanofi

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
SNY

Zacks

2 months ago

Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
SNY

Pharmaceutical Technology

2 months ago

FDA fast tracks Sanofi’s mRNA vaccine for chlamydia

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
SNY

Zacks

2 months ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
SNY

GlobeNewswire

2 months ago

Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
SNY

Zacks

2 months ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
SNY

GlobeNewswire

2 months ago

Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis

Press Release: Availability of the Q1 2025 Aide mémoire
SNY

GlobeNewswire

2 months ago

Press Release: Availability of the Q1 2025 Aide mémoire

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
SNY

Zacks

2 months ago

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls
SNY

The Fly

2 months ago

FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout
SNY

Bloomberg

2 months ago

Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout

Share on Social Networks: